←
Intensity Therapeutics773 posts
Intensity Therapeutics avatar

Intensity Therapeutics

@IntensityInc

Intensity Therapeutics is a clinical stage, biotechnology company whose mission is to create safer and more efficacious cancer therapies. Nasdaq: $INTS

◷ Joined February 2013▧ 181 Photos and videos
Intensity Therapeutics avatar
Intensity Therapeutics@IntensityInc·Nov 17

Can treating cancer directly at the tumor site change how we approach difficult-to-treat solid tumors? Our CEO Lew Bender was featured in @digitaljournal, discussing how investigational INT230-6 is designed to attack tumors directly while stimulating a broader immune response. From a 75% disease control rate in our Phase 1/2 monotherapy study to promising preliminary INVINCIBLE-4 data, Lew shares how we're exploring new approaches to treating difficult-to-treat solid tumors. 🔗 Read the full Q&A: digitaljournal.com/article/q…

Intensity Therapeutics avatar
Intensity Therapeutics@IntensityInc·Nov 11

It was great to be at the inaugural Future of Oncology Summit, where our CEO Lew Bender had the opportunity to connect with Daniel H. O'Keefe (@okeefe), Commissioner of Connecticut's Department of Economic and Community Development and the state's first Chief Innovation Officer, and Jodie Gillon, President and CEO of @BioCT_org! We were proud to join leaders across science, biotech and healthcare in conversations advancing cancer research and exploring new opportunities for innovation! $INTS

Post attachment
Intensity Therapeutics avatar
Intensity Therapeutics@IntensityInc·Nov 10

$INTS Founder & CEO Lewis Bender joins @biospace's Denatured podcast to explore the potential of intratumoral therapies and how investigational INT230-6 is designed to kill tumors locally while stimulating an immune response. 🎧 Watch here: biospace.com/drug-developmen…

Intensity Therapeutics avatar
Intensity Therapeutics@IntensityInc·Oct 29

Every patient can add to what we know. Preliminary data from the first 14 patients (seven in each cohort) showed a 71% pathological complete response ("pCR") in patients receiving INT230-6 in Cohort A and a 42% pCR in patients receiving the SOC alone (Cohort B). Those insights continue to inform our understanding of INT230-6. #BreastCancerAwarenessMonth $INTS

Post attachment
Intensity Therapeutics avatar
Intensity Therapeutics@IntensityInc·Oct 27

$INTS was pleased to connect with colleagues from the Swiss Cancer Institute, including Dr. Markus Joerger and Charlotte Micheloud at #ESMO2026! Our Founder, President and CEO Lewis H. Bender was joined by Kim Guedes, Intensity’s Vice President of Clinical Operations, as they connected with fellow researchers and members of the oncology community. Opportunities like ESMO bring together the people, ideas and collaborations helping advance cancer research. We're grateful for the opportunity to connect with colleagues who share our commitment to exploring new approaches to cancer treatment.

Post attachmentPost attachment
Intensity Therapeutics avatar
Intensity Therapeutics@IntensityInc·Oct 23

New INVINCIBLE4 data is coming to  @‌myESMO's 2026 conference! $INTS reported encouraging early results from the first 7 patients in Cohort A, including pCR in the breast and affected lymph nodes in 5 of 7 patients. The ePoster will be available beginning Oct. 23. 🔗: bit.ly/4iAkspz #ESMO26

Post attachment
Intensity Therapeutics avatar
Intensity Therapeutics@IntensityInc·Oct 20

Progress is built study by study. In July 2026, the Company restarted patient treatment in the INVINCIBLE-4 Study. This is Phase 2 open-label, randomized controlled, multicenter study to analyze the clinical activity, safety, and tolerability of INT230-6 given before SOC in patients with early-stage, operable TNBC #BreastCancerAwarenessMonth

Post attachment
Intensity Therapeutics avatar
Intensity Therapeutics@IntensityInc·Oct 19

Why has intratumoral cancer treatment remained so challenging? In a new byline for Drug Delivery Leader, Intensity Therapeutics Founder and CEO Lew Bender explores the history of intratumoral cancer therapies, the scientific barriers that have limited their success, and why novel drug formulations may help move the field forward. Read Lew's full perspective in Drug Delivery Leader: bit.ly/3VMnSNf